SI2880053T1 - Blažitev poškodbe tkiva in fibroze s protitelesom proti-LTBP4 - Google Patents

Blažitev poškodbe tkiva in fibroze s protitelesom proti-LTBP4

Info

Publication number
SI2880053T1
SI2880053T1 SI201331718T SI201331718T SI2880053T1 SI 2880053 T1 SI2880053 T1 SI 2880053T1 SI 201331718 T SI201331718 T SI 201331718T SI 201331718 T SI201331718 T SI 201331718T SI 2880053 T1 SI2880053 T1 SI 2880053T1
Authority
SI
Slovenia
Prior art keywords
tissue damage
via anti
fibrosis via
mitigating tissue
ltbp4
Prior art date
Application number
SI201331718T
Other languages
English (en)
Inventor
Elisabeth M. MCNALLY
Ahlke Heydemann
Ermelinda Ceco
Original Assignee
Ikaika Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ikaika Therapeutics, Llc filed Critical Ikaika Therapeutics, Llc
Publication of SI2880053T1 publication Critical patent/SI2880053T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201331718T 2012-08-01 2013-08-01 Blažitev poškodbe tkiva in fibroze s protitelesom proti-LTBP4 SI2880053T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261678564P 2012-08-01 2012-08-01
PCT/US2013/053255 WO2014039189A1 (en) 2012-08-01 2013-08-01 Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
EP13835243.0A EP2880053B8 (en) 2012-08-01 2013-08-01 Mitigating tissue damage and fibrosis via anti-ltbp4 antibody

Publications (1)

Publication Number Publication Date
SI2880053T1 true SI2880053T1 (sl) 2020-08-31

Family

ID=50025687

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331718T SI2880053T1 (sl) 2012-08-01 2013-08-01 Blažitev poškodbe tkiva in fibroze s protitelesom proti-LTBP4

Country Status (15)

Country Link
US (9) US9873739B2 (sl)
EP (2) EP2880053B8 (sl)
AU (5) AU2013313282B2 (sl)
CA (1) CA2880649C (sl)
CY (1) CY1123029T1 (sl)
DK (1) DK2880053T3 (sl)
ES (1) ES2791778T3 (sl)
HK (1) HK1211307A1 (sl)
HR (1) HRP20200818T1 (sl)
HU (1) HUE049217T2 (sl)
PL (1) PL2880053T3 (sl)
PT (1) PT2880053T (sl)
RS (1) RS60318B1 (sl)
SI (1) SI2880053T1 (sl)
WO (1) WO2014039189A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3142750T1 (sl) 2014-05-13 2020-11-30 The Trustees Of The University Of Pennsylvania Sestavki, ki vsebujejo AAV izražen dvojni protitelesni konstrukt in uporaba le-tega
US20170232276A1 (en) * 2014-09-30 2017-08-17 Primegen Biotech, Llc Treatment of fibrosis using deep tissue heating and stem cell therapy
KR20160101692A (ko) 2015-02-17 2016-08-25 한국전자통신연구원 다채널 신호 처리 방법 및 상기 방법을 수행하는 다채널 신호 처리 장치
AU2016275909A1 (en) 2015-05-13 2017-11-09 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
KR20190135000A (ko) 2017-02-28 2019-12-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Aav 벡터를 기반으로 하는 인플루엔자 백신
CN110741082A (zh) 2017-02-28 2020-01-31 宾夕法尼亚州大学信托人 腺相关病毒(aav)进化枝f载体及其用途
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
EP3897689A1 (en) 2018-12-21 2021-10-27 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5372807A (en) 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
DE60027135T2 (de) 1999-01-21 2007-01-11 Metamorphix, Inc. Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
IL146845A0 (en) 1999-07-20 2002-07-25 Pharmexa As Method for down-regulating gdf-8 activity
EP1593689A3 (en) 2000-01-18 2006-04-05 Ovita Limited Myostatin and mimetics thereof
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
WO2002040468A1 (en) 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
CA2476654A1 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
US20040138118A1 (en) 2002-09-16 2004-07-15 Neil Wolfman Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2004058988A2 (en) 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
WO2004083241A2 (en) 2003-03-19 2004-09-30 Takeda Pharmaceutical Company Limited Btc-interacting proteins and use thereof
EP1729793B1 (en) 2004-03-02 2015-07-22 Acceleron Pharma Inc. Alk7 and myostatin inhibitors for muscle wasting disorders
EP1733041B1 (en) 2004-03-23 2012-05-09 Eli Lilly & Company Anti-myostatin antibodies
DE602005026386D1 (de) 2004-06-28 2011-03-31 Univ Western Australia Antisense-oligonukleotide zur induktion von exon-skipping sowie verfahren zur verwendung davon
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
JP2008506787A (ja) 2004-07-29 2008-03-06 シェーリング−プラウ・リミテッド 動物においてミオスタチン活性を調節または阻害して赤身組織の成長増加を導くａｌｋ５インヒビターの使用
AU2006239860B2 (en) 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
AU2009270793A1 (en) * 2008-07-18 2010-01-21 Oragenics, Inc. Compositions for the detection and treatment of colorectal cancer
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
FR2943249B1 (fr) 2009-03-18 2011-08-12 Genethon Utilisation de la decorine pour augmenter la masse musculaire
EP2424560A4 (en) 2009-03-23 2013-11-27 Inst Medical W & E Hall Compounds and methods modulating an immune response
JP5931720B2 (ja) 2009-05-08 2016-06-08 クルナ・インコーポレーテッド Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
WO2012006181A2 (en) * 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer

Also Published As

Publication number Publication date
RS60318B1 (sr) 2020-07-31
CY1123029T1 (el) 2021-10-29
US20230235044A1 (en) 2023-07-27
AU2013313282A1 (en) 2015-02-26
EP2880053A4 (en) 2016-03-09
AU2019222850A1 (en) 2019-09-19
WO2014039189A1 (en) 2014-03-13
DK2880053T3 (da) 2020-05-11
US9873739B2 (en) 2018-01-23
US20180134785A1 (en) 2018-05-17
AU2021200783B2 (en) 2022-10-06
US20190256589A1 (en) 2019-08-22
US20200123247A1 (en) 2020-04-23
US20200385457A1 (en) 2020-12-10
AU2022271391A1 (en) 2022-12-15
HRP20200818T1 (hr) 2020-08-07
PL2880053T3 (pl) 2021-01-11
US20220089717A1 (en) 2022-03-24
US20190002557A1 (en) 2019-01-03
AU2018200078A1 (en) 2018-01-25
EP2880053B1 (en) 2020-02-26
US20210238274A1 (en) 2021-08-05
ES2791778T3 (es) 2020-11-05
HUE049217T2 (hu) 2020-09-28
EP2880053B8 (en) 2020-04-15
PT2880053T (pt) 2020-05-22
US20140037637A1 (en) 2014-02-06
AU2021200783A1 (en) 2021-03-04
HK1211307A1 (en) 2016-05-20
EP3711771A1 (en) 2020-09-23
EP2880053A1 (en) 2015-06-10
CA2880649C (en) 2023-03-14
CA2880649A1 (en) 2014-03-13
AU2013313282B2 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
HUS2100012I1 (hu) 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók
EP2833849A4 (en) INTRAOCULAR DELIVERY DEVICES AND ASSOCIATED METHODS
EP2895123A4 (en) EXPANDABLE OCULAR IMPLANT DEVICES AND ASSOCIATED METHODS
EP2840951A4 (en) METHODS AND DEVICES FOR TISSUE RETRACTION
EP2773274A4 (en) DEVICES AND METHODS FOR TISSUE EXTRACTION
EP2723255A4 (en) DEVICES AND METHODS FOR TISSUE EXTRACTION
AP4055A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EP2770899A4 (en) TISSUE AND CELL IMAGING
PL2880053T3 (pl) Łagodzenie uszkodzenia tkanek i włóknienia przez przeciwciało przeciwko ltbp4
EP2722625A4 (en) SHREDDING AND DRYING DEVICE
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
EP2558137A4 (en) METHODS AND COMBINATION
GB201216649D0 (en) Agents and methods
EP2855769A4 (en) PAPER-MOUCHOIR COMPRISING MACROALGUES
EP2931140A4 (en) Tissue repair equipment and methods
EP2697386A4 (en) DESIGN AND USE OF PEPDUCINE
GB201117106D0 (en) Prosthesis and methods and uses involving said prosthesis
IL229303A0 (en) Devices and methods to fasten tissue
EP2663343A4 (en) DEVICES AND METHODS FOR TISSUE ENGINEERING
EP2852662A4 (en) HERPESVIRUS COMPOSITIONS AND RELATED METHODS
GB2504303B (en) Earphones and earplugs
GB201001384D0 (en) Light-fitting and associated methods
PT2734522T (pt) 4-imidazopiridazina-1-il-benzamidas e 4-imidazotriazin-1- il-benzamidas como inibidores de btk
TWM432399U (en) Improved earmuff structure
TWM433704U (en) Slidable and rotatable hinge